摘要
目的:对2015-2020年发表的中医药治疗免疫球蛋白A(Immunoglobulin A,IgA)肾病系统评价/Meta分析进行再评价研究。方法:计算机检索中国知网、PubMed等数据库,收集中医药治疗IgA肾病的系统评价/Meta分析文献,检索时限为2015年1月1日-2020年12月31日。采用AMSTAR2量表和GRADE方法分别对纳入文献进行方法学质量评价和证据质量分级。结果:共纳入8篇系统评价/Meta分析文献,AMSTAR2量表评价所纳入的研究文献显示方法学质量整体偏低,其中4篇低质量,4篇极低质量。GRADE工具对结局指标进行证据体评价,涉及18个主要结局指标,其中5个中等级别,6个低等级别,7个极低级别。结论:纳入的研究文献方法学质量和证据质量普遍不高,建议加强顶层设计,遵循科学范式,为医疗决策者提供更高层次的循证证据。
Objectives:A re-evaluation study was conducted on the systematic review/meta-analysis of TCM treatment of IgA nephropathy published from 2015 to 2020.Methods:In CNKI,PubMed and other databases,systematic reviews/meta-analysis literature on the treatment of IgAN in TCM were collected by computer,the search time limit was from January 1,2015 to December 31,2020.The AMSTAR2 scale and GRADE method were used to evaluate the methodological quality of the included literature and grade the quality of evidence,respectively.Results:A total of 8 systematic reviews/meta-analysis articles were included.The research articles included in the AMSTAR2 scale evaluation showed that the methodological quality was generally low,including 4 articles of low quality and 4 articles of extremely low quality.GRADE tool evaluated the outcome indicators of the evidence body,involving 18 main outcome indicators,of which 5 were medium-level,6 were low-level,and 7 were very low-level.Conclusion:The methodological quality and evidence quality of the included research are generally not high.It is recommended to strengthen the top-level design,follow the scientific paradigm,and provide higher-level evidence-based evidence for medical decision-makers.
出处
《中医临床研究》
2022年第11期135-138,共4页
Clinical Journal Of Chinese Medicine
基金
国家自然科学基金项目(基于外泌体miR-210调控低氧-糖酵解促血管新生机制研究益肾活血方抗肾纤维化效应82060820)。
